Gain Therapeutics is trading 5.26% down now at $1.26, amid broad market and biotechnology weakness; no company-specific catalyst has been confirmed. - No company-specific announcement explaining the October 16, 2026 decline surfaced in available search results; the latest listed company updates predate the session. - Reports cite investor concern about sticky inflation, potential rate hikes and debt-funded AI spending; biotechnology stocks were also lower.